CureVac Shareholders Face Final Chapter as BioNTech Merger Nears Completion

CureVac NL0015436031

For equity holders in CureVac, the calendar year 2026 marks the definitive conclusion of an era. The period of volatile share price movements driven by clinical trial data is now over, with the acquisition by BioNTech being effectively finalized. Investors are no longer watching for new research breakthroughs but are instead facing the inevitable delisting of the stock, which currently exists merely as a technical placeholder for the transaction's settlement.

The stock's pricing mechanism has completely detached from the company's operational performance. Neither pipeline developments nor quarterly financial results hold any relevance for its valuation. The reason is straightforward: BioNTech has now secured over 86 percent of CureVac's shares. This surpasses the critical threshold granting the Mainz-based firm complete control.

Consequently, the current share price of $4.52 no longer reflects future prospects but is purely mathematically tied to the takeover offer. The equity now functions solely as a vehicle for the predetermined exchange ratio. All the volatility that once characterized this biotech stock has been replaced by a static valuation.

The Path to Delisting and Integration

Having secured a majority, BioNTech has initiated a "squeeze-out" procedure. This legal process allows the acquirer to compel remaining minority shareholders to sell their shares for a defined compensation. For investors still holding the stock, the window for open market trading is closing rapidly.

The integration roadmap involves several key steps:
* Consolidation: CureVac's entire mRNA pipeline and technological infrastructure will be absorbed into BioNTech.
* Delisting: The stock's listing on the Nasdaq Global Market will be terminated in the near term.
* Settlement: Any remaining shareholdings will be automatically liquidated or transferred as part of the legal process.

This concludes the story of CureVac as an independent publicly traded company. The ongoing 2026 fiscal year serves only to complete administrative formalities, until the ticker symbol is permanently removed from trading boards and the technology platform is fully absorbed into the new owner's portfolio.